Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:32 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2137–2160 of 2,691 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal saline solution Clear all

Conditions: Opioid Use Disorder, Back Pain, Stress
Interventions: Placebo, Oxycodone, Naloxone; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Pouch, Ileal, Fistula
Interventions: Ossium vBM-MSC, Placebo; Drug · Other
Lead sponsor: Anthony Lembo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions: Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Down Syndrome
Interventions: Insulin glulisine, Saline; Drug
Lead sponsor: HealthPartners Institute; Other
Eligibility: 35 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Multiple Sclerosis
Interventions: Ferumoxytol; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anaphylaxis
Interventions: Intravenous heparin, Saline; Drug
Lead sponsor: University of Missouri, Kansas City; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Kansas City, Missouri

Conditions: Tracheostomy, Endotracheal Tube, Ventilator Associated Pneumonia, Tracheitis, Microbial Colonization, Pediatric Infectious Disease, Pediatrics
Interventions: Suctioning of artificial airway; Diagnostic Test
Lead sponsor: Northwell Health; Other
Eligibility: 0 Years to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Queens, New York

Conditions: Fractures, Closed, Wounds and Injuries
Interventions: cefazolin, Placebo; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Bacterial Infections
Interventions: QPX9003 for IV Infusion, Placebo for IV infusion; Drug
Lead sponsor: Qpex Biopharma, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Cypress, California

Conditions: Pain
Interventions: naloxone, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Coagulation; Intravascular, Rotational Thromboelastometry, Fibrinolysis; Hemorrhage, Tranexamic Acid, Total Hip Arthroplasty
Interventions: Tranexamic Acid, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm, Primary Liver Cancer, Liver Neoplasm
Interventions: Lumason, Sonazoid; Diagnostic Test
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Cancer, BRCA Mutation
Interventions: Tranexamic acid, Normal saline; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: CRPS, Chronic Regional Pain Syndrome
Interventions: Etanercept, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 10 Years to 17 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension
Interventions: Abatacept, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension, End Stage Renal Disease
Interventions: Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Liposomal Bupivacaine 13.3, Bupivacaine, Placebo; Drug · Other
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Osteoarthritis of the Knee
Interventions: TLC599, DSP, Normal Saline; Drug · Other
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 40 Years and older
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 33 more

Conditions: Mucositis, Head and Neck Cancer
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Safety and Efficacy of Intranasal Dexmedetomidine
Interventions: Dexmedetomidine, Midazolam Hydrochloride, Nitrous Oxide; Drug
Lead sponsor: Bon Secours Pediatric Dental Associates; Other
Eligibility: 3 Years to 6 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Th17 Helper Immune Cells, Autoimmunity, Salt Intake, Sodium Chloride
Interventions: Low salt diet, Low salt diet + IV normal saline, Liberal salt diet; Dietary Supplement
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Triple Negative Breast Neoplasms
Interventions: Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 47
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more

Conditions: Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions: placebo, iv sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 0 Days to 4 Days
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 20
States / cities: Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more

Conditions: Total Knee Arthroplasty
Interventions: Continuous femoral catheter block, Lidocaine, Preservative free normal saline; Procedure · Drug · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Loma Linda, California

Search by objective public record fields.

Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms

Study of Ossium Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in the Setting of Crohn's Disease

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging

Intravenous Heparin as an Adjunct for the Treatment of Anaphylactic Reactions in an Emergency Department

Airway Microbiome Changes After Artificial Airway Exchange in Critically-ill Pediatric Patients.

Antibiotic Prophylaxis in Orthopaedic Traumatology

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

Subjective Analgesic Effects of Naloxone and Virtual Reality

The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery

Y-90 Treatment Response Using Transarterial Radioembolization

Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage

TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial

Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer

Safety and Efficacy of Intranasal Dexmedetomidine

Salt and TH-17 in Healthy Human Subjects

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

Treatment of Postoperative Pain After Total Knee Arthroplasy Using Intravenous Lidocaine Infusion